Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Tranzyme Pharma Says That First Phase 3 Pivotal Trial Of Ulimorelin Failed

Late-stage biopharmaceutical company Tranzyme Pharma (TZYM: Quote), on Monday, along with specialty pharmaceutical company Norgine B.V., announced top-line results of the primary analysis of ULISES 007, the first of two Phase 3 pivotal trials evaluating ulimorelin.

The company stated that the trial failed to meet its primary and secondary efficacy endpoints.

Tranzyme further stated that the results of ULISES 007 showed that ulimorelin, at both 160 and 480 micrograms/kg doses, was not statistically different from placebo for the primary endpoint.

"These results are surprising and disappointing. While we are still planning to analyze the data from the second phase 3 trial ULISES 008, which we expect by the end of the second quarter, we are stopping all other NDA activities for ulimorelin," said Vipin K. Garg, Ph.D., President and Chief Executive Officer, Tranzyme Pharma.

Click here to receive FREE breaking news email alerts for Tranzyme Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Europe's passenger car registrations continued to rise in August, pursuing the upward trend commenced twelve months ago, the European Automobile Manufacturers Association reported Wednesday. Car sales increased 2.1 percent in August and 5.6 percent in July. Overall, 688,464 new cars were registered... Stocks moved notably higher over the course of the trading day on Tuesday after recovering from an initial move to the downside. With the strong upward move on the day, the Dow reached a new record intraday high before giving back some ground. President Barack Obama is scheduled to travel to the headquarters of the Centers for Disease Control and Prevention in Atlanta, Georgia, on Tuesday to outline steps the U.S. will take to help combat the Ebola outbreak in West Africa.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.